The FDA and Aduhelm: WTF?
World of DTC Marketing
JUNE 23, 2021
SKIMMERS SUMMARY: Jefferies analysts found doctors have shown strong interest in prescribing Aduhelm for about 35% of early-stage Alzheimer’s patients with mild cognitive impairment after surveying 50 U.S. Not to mention the $56,000 annual price tag. neurologists or psychiatrists currently treating about 12,000 Alzheimer’s patients.
Let's personalize your content